2. GPCR/G Protein Neuronal Signaling
  3. Orexin Receptor (OX Receptor)
  4. Vonlerolizumab

Vonlerolizumab  (Synonyms: Pogalizumab; MOXR 0916)

Cat. No.: HY-P99249 Purity: 99.70%
COA
SDS
Technical Support

Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models.

For research use only. We do not sell to patients.

CAS No. : 1638935-72-4

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Vonlerolizumab Featured Recommendations:

Vonlerolizumab Related Antibodies

Top Publications Citing Use of Products

View All Orexin Receptor (OX Receptor) Isoform Specific Products:

View All Isoforms
OX2 Receptor OX1 Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
IC50 & Target

TNFRSF4/OX40/CD134
In Vitro

Vonlerolizumab (0.01 nM-10 μM) activates NF-κB in Jurkat cells[1].
Vonlerolizumab (1 pM-1 μM, 96 h) enhances the proliferation of CD4+ and CD8+ T cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vonlerolizumab Related Antibodies
In Vivo

Vonlerolizumab (250 μg/dose, i.p., 2 doses) prolongs tumor growth and median survival in mouse models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CT26 colon cancer model established in BALB/c mice and MCA-205 fibrosarcoma model established in C57BL/6 mice[1]
Dosage: 250 μg/dose
Administration: Intraperitoneal injection (i.p.), 2 doses
Result: Delayed the growth of the tumor, but it still progressed eventually.
Significantly prolonged median survival period of mice.
Exhibited the anti-tumor depending on CD4+ T cells and once CD4+ cells was removed, its effect basically disappeared.
Gene ID

7293  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

145.26 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Vonlerolizumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation

Purity: 99.70%

SDS (251 KB)

COA (232 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Vonlerolizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vonlerolizumab1638935-72-4Pogalizumab MOXR 0916MOXR0916MOXR 0916MOXR-0916Orexin Receptor (OX Receptor)Hypocretin ReceptorHCRT Receptoratezolizumabtumorsolid malignanciesmonoclonalInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vonlerolizumab
Cat. No.:
HY-P99249
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.